舒必利是一种非典型抗精神病药物，是主要用于治疗精神病与精神分裂症和抑郁症相关疾病的苯甲酰胺类药物（商品名：Meresa， Bosnyl， Dogmatil， Dolmatil， Eglonyl）。舒必利更常用于欧洲和日本。在美国和加拿大，到目前为止它已不被批准。此药有和相关的抗精神病药物阿米舒必利（amisulpride）的强大化学作用和临床相似之处。

医学导航：心理学／精神病学

心理历程

障碍（o, p, m, p, a, d, s）
症状／齐名／涉及

操作（评估／治疗）
药物（N5A/5B/5C/6A/6B/6D）

Sulpiride (brand names Dogmatil (HK, SG, PH), Dolmatil (IE, UK), Eglonyl (RU, ZA), Espiride (ZA), Modal (IL), Prometar (UY), Sulpor (UK) and others) is an atypical antipsychotic drug (although some texts have referred to it as a typical antipsychotic) of the benzamide class used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Europe, Russia and Japan. Levosulpiride is its purified levo-isomer and is sold in India for similar purpose. So far it has not been approved in the United States, Canada and Australia. The drug is chemically and clinically similar to amisulpride.